Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis

Blood. 2010 Sep 16;116(11):1990-1. doi: 10.1182/blood-2010-07-295485.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Amyloidosis / blood
  • Amyloidosis / drug therapy*
  • Antineoplastic Agents / therapeutic use
  • Dexamethasone / therapeutic use
  • Disease-Free Survival
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunoglobulin Light Chains / blood
  • Lenalidomide
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Glucocorticoids
  • Immunoglobulin Light Chains
  • Thalidomide
  • Dexamethasone
  • Lenalidomide